VIP (Vasoactive Intestinal Peptide)
Vasoactive Intestinal Peptide — 28-amino-acid neuropeptide researched for anti-inflammatory and pulmonary applications
Half-life
~2 min (peripheral)
Typical Dose
50 mcg daily (often intranasal)
Format
Injectable
Purity
≥98%
Overview
VIP is an endogenous 28-amino-acid neuropeptide with potent anti-inflammatory, vasodilatory, and immunomodulatory effects. It has been studied extensively in the Chronic Inflammatory Response Syndrome (CIRS) community — notably as part of Dr. Ritchie Shoemaker's protocol for mold toxicity — as well as in pulmonary research, sarcoidosis, and gut inflammation.
Mechanism
VIP activates two G-protein coupled receptors (VPAC1 and VPAC2), leading to downregulation of NF-kB and Th1/Th17 inflammatory pathways and upregulation of regulatory T cells. It also acts as a vasodilator and bronchodilator via cAMP signaling. The combined anti-inflammatory and vascular effects underpin its research applications in chronic inflammatory and pulmonary conditions.
Researched benefits
- Anti-inflammatory and immunomodulatory
- CIRS protocol support (Shoemaker approach)
- Mold toxicity research
- Pulmonary and sarcoidosis research
- Regulatory T-cell induction
- Vasodilatory and bronchodilatory effects
Frequently asked
What is the Shoemaker CIRS protocol and where does VIP fit?
Dr. Ritchie Shoemaker developed a multi-step protocol for Chronic Inflammatory Response Syndrome, typically associated with biotoxin (mold) exposure. VIP is positioned as the final step — used only after the subject has removed exposure, corrected MARCoNS, normalized MSH, and stabilized other markers. In this framework, VIP restoration is thought to reset downstream immune and hormonal dysregulation.
Why intranasal vs injection?
The Shoemaker CIRS protocol uses compounded intranasal VIP for direct delivery and convenience. Research-use subcutaneous injection is also used. Given the very short peripheral half-life (~2 min), frequent dosing or sustained-delivery formulations may be required depending on endpoint.
Is VIP appropriate before mold exposure is resolved?
Most CIRS research protocols discourage initiating VIP before ongoing biotoxin exposure is removed and upstream markers (C4a, TGF-beta1, MSH) are normalized, as administering VIP in an unresolved inflammatory state is reported to be poorly tolerated.
Ready to start your research
Get VIP (Vasoactive Intestinal Peptide) from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy VIP (Vasoactive Intestinal Peptide) now